文献速递流行病学与生物统计医学教育与科研方法

系统调查显示系统评价中药物安全性评估方法存在重要局限

A systematic survey showed important limitations in the methods for assessing drug safety among systematic reviews.
PubMed 文献 · J Clin Epidemiol · 2020-04-01

该横断面调查随机抽取2015年发表的120篇系统评价(Cochrane与非Cochrane各60篇),评估其药物安全性结局的设计、实施与分析。多数评价检索了主要数据库并独立双人筛选,但仅7.5%清晰定义安全性结局,5.8%定义主要安全性结局且均未预设定。Cochrane评价在提供方案、方法学家参与和GRADE评估方面显著优于非Cochrane评价。

要点

  • 仅7.5%的系统评价清晰定义安全性结局,5.8%定义主要安全性结局且均未预设定。
  • 合并二分类安全性数据的80篇评价中,41%探索异质性来源或报告GRADE证据质量。
  • Cochrane评价在提供方案、方法学家参与和GRADE评估方面显著优于非Cochrane评价。

核心结论

  • 系统评价中药物安全性评估的规划与分析存在重要改进空间。
  • Cochrane评价在方法学上优于非Cochrane评价,但多数评价未预设定安全性结局或分析方法。

研究设计与样本

  • 横断面调查,检索PubMed识别2015年发表在Cochrane系统评价数据库和核心临床期刊的系统评价。
  • 随机抽取120篇评估药物效应的系统评价,Cochrane与非Cochrane按1:1比例各60篇。
  • 由两名研究者独立筛选并采用预设标准化问卷收集数据。

主要发现

  • 大多数评价检索了PubMed/MEDLINE(n=117, 97.5%)、EMBASE(n=105, 87.5%)和Cochrane CENTRAL(n=110, 91.7%)。
  • 多数评价进行了独立双人研究筛选(n=98, 81.7%)、偏倚风险评估(n=105, 87.5%)和数据收集(n=105, 87.5%)。
  • 仅9篇(7.5%)清晰定义安全性结局,7篇(5.8%)定义主要安全性结局,且均未说明主要安全性结局是否预设定。
  • 合并主要二分类安全性数据的80篇评价中,仅33篇(41%)进行亚组分析探索异质性来源或报告GRADE证据质量评估。
  • Cochrane评价更常提供研究方案(100% vs. 23.3%; P < 0.001)、纳入方法学家(53.3% vs. 20.0%; P < 0.001)和报告主要安全性结局的GRADE评估(70.6% vs. 19.6%; P < 0.001)。

临床怎么用

  • 开展药物安全性系统评价时,应预先设定安全性结局和分析方法。
  • 合并安全性数据时应探索异质性来源并采用GRADE评估证据质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to examine the design, conduct, and analysis of systematic reviews assessing drug safety through a cross-sectional survey. STUDY DESIGN AND SETTING: We searched PubMed to identity systematic reviews published in the Cochrane Database of Systematic Reviews and Core Clinical Journals indexed in 2015 and randomly sampled systematic reviews assessing drug effects at a 1:1 ratio of Cochrane and non-Cochrane reviews. Teams of two investigators independently conducted study screening and collected data, using prespecified, standardized questionnaires. In addition to general information, we collected details about the planning and analyses of safety outcomes. RESULTS: We included 120 systematic reviews, including 60 Cochrane and 60 non-Cochrane reviews. Most reviews searched PubMed/MEDLINE (n = 117, 97.5%), EMBASE (n = 105, 87.5%), and Cochrane CENTRAL (n = 110, 91.7%) and conducted independent and duplicate study selection (n = 98, 81.7%), risk of bias assessment (n = 105, 87.5%), and data collection (n = 105, 87.5%). Only nine (7.5%) reviews clearly defined safety outcomes, and seven (5.8%) defined a primary safety outcome; none stated whether the primary safety outcome was predefined. Among the 80 reviews that pooled the primary dichotomous safety data across studies, less than half (41%, n = 33) conducted subgroup analysis to explore for sources of heterogeneity or reported a GRADE assessment for the overall quality of evidence. Cochrane reviews were more likely to provide a study protocol (100% vs. 23.3%; P < 0.001), involve methodologists (53.3% vs. 20.0%; P < 0.001), and report a GRADE assessment for the primary safety outcome (70.6% vs. 19.6%; P < 0.001). CONCLUSION: Our findings highlighted areas for improved planning and analysis in the assessment of drug safety among systematic reviews. Cochrane reviews were superior to non-Cochrane reviews; however, most reviews did not prespecify their safety outcomes or methods for analysis, explore sources of heterogeneity among pooled effects, or assess the overall quality of evidence with the GRADE approach.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Li L, Deng K, Busse JW, et al. A systematic survey showed important limitations in the methods for assessing drug safety among systematic reviews. J Clin Epidemiol. 2020. PMID: 32247024. doi:10.1016/j.jclinepi.2020.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。